

FOI 2297

08/04/2024

FREEDOM OF INFORMATION ACT 2000 – INFORMATION REQUEST

I have a freedom of information request regarding the treatment of certain types of lung cancer. Could you please tell me how many early-stage (non-metastatic or Stages 1-3) non-small cell lung cancer (NSCLC) patients were treated in the past 3 months with:

- Atezolizumab (Tecentriq)
- Durvalumab (Imfinzi)
- Nivolumab (Opdivo)
- Pembrolizumab (Keytruda)
- Chemotherapy
- Radiotherapy
- Chemotherapy AND Radiotherapy

Response:

- Atezolizumab (Tecentriq) – 0 patients
- Durvalumab (Imfinzi) – 3 patients
- Nivolumab (Opdivo) – 0 patients
- Pembrolizumab (Keytruda) – 0 patients
- Chemotherapy – 0 patients
- Radiotherapy – 0 patients
- Chemotherapy AND Radiotherapy – 0 patients

Email: Foi.Team@Southerntrust.hscni.net